Big Buttons

• Full of sound and fury, signifying nothing

  Novo Nordisk tried to convince the FDA that semaglutide injections are difficult to compound. (Spoiler: They aren't.) read more →

• Video: APC on Scripps

  APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide. read more →

• BREAKING: FDA allows renewed compounding of tirzepatide copies — for now

  In a win for continued patient access to compounded versions of Eli Lilly’s Mounjaro and Zepbound, FDA clarified today that pharmacies may continue to prepare copies of those FDA-approved drugs, at least for now. read more →

• FDA issues IV fluids emergency guidance

  The FDA has published emergency guidance that empowers pharmacies to help address the nationwide IV solutions shortage. read more →

• Welcome aboard, GYMA

  It's our newest tier-level corporate patron. read more →

• The Journey to Earning the CPhT-Adv Certification from PTCB

  Earning the Advanced Certified Pharmacy Technician Certification from the Pharmacy Technician Certification Board is a great way to boost your professional skills and career opportunities. read more →

• Technicians: Professional Development through Mentorship

  Mentors play a crucial role in career advancement by offering guidance, encouragement, advocacy, and networking potential. Identifying the right mentor within your industry is essential. read more →

• FDA reconsiders on tirzepatide, big questions remain

  After a court order, the FDA agreed to reconsider taking tirzepatide off the shortage list. read more →

More News

Upcoming Events

February 20: APC CE webinar: Navigating Marketing and 503B Sourcing: Best Practices for Compounding Pharmacies

March 14–16: APC Owner Summit, Destin, FL

March 27–29: Personalized Medicine Course II: Gastroenterology, Infectious Disease, Dermatology; Houston, TX (in-person and online option)

July 18-20: Personalized Medicine Course I: Endocrinology; virtual

September 16–17: APC Compounders on Capitol Hill, Washington, DC

November 7–9: Personalized Medicine Course III: Memory Maintenance, Neurology, Psychiatry, How to Interpret Functional Medicine Labs; Scottsdale, AZ

The Latest Resources for Compounders

• Best Practices for Compounding Shortage Drugs
• Best Practices for Marketing Compounded Medications
• Best Practices for Compounding Ketamine
• Best Practices for Clinic Direct Billing (Office Pay)
• Brief on Compounded GLP-1 Drugs and Patient Adverse Events
• Statement on Peptide Compounding
• Statement on Constructive Transfer

Click here for more resources for compounding professionals

APC In the News

Not holding back:

We pull no punches in this article about Novo's latest shenanigans

Video appearance: APC talks the legal issues:

APC CEO Scott Brunner was a guest on "On The Pen" — a YouTube channel dedicated to all things GLP-1.

PharmExec features APC execs talking about the compounding process:

From the manufacturing process to patient and provider challenges, this PharmExec video interview covers all things compounding.

APC calls out Novo in Reuters:

Reuters used our comment that there's a difference between making molecules and compounding with them.

CBS quotes APC on resolving shortages:

Taking a different angle, this article looked how the FDA decides when to resolve a shortage.

The Brits could have done better:

UK-based pharmaphorum is covering the GLP-1 issue, but it played down our rather important point about the ease of compounding with the drugs.

Video: APC on Scripps:

APC CEO Scott Brunner appeared on the Scripps News show “America On The Docket,” talking about the “brewing legal battle” over compounded tirzepatide and semaglutide.

Tirzepatide fallout in The Hill:

The Hill writes one of the first stories on the fallout from the FDA's tirzepatide decision.

Click here for more examples of APC in the news

Support Compounding

Our Patrons